Literature DB >> 1666499

Mechanism of action of sparfloxacin against and mechanism of resistance in gram-negative and gram-positive bacteria.

L J Piddock1, M Zhu.   

Abstract

The inhibition of DNA synthesis by sparfloxacin; accumulation of sparfloxacin into members of the family Enterobacteriaceae, Pseudomonas aeruginosa, and staphylococci; induction of recA in Escherichia coli; and the optimum bactericidal concentration (OBC) were measured, and killing kinetics at the OBC were estimated. The OBC and maximum recA-inducing concentration in E. coli were both 1 microgram of sparfloxacin per ml. Accumulation was rapid; two- to threefold more sparfloxacin than ciprofloxacin accumulated in staphylococci and more sparfloxacin accumulated in staphylococci than in gram-negative bacteria. Laboratory mutants with decreased susceptibilities to quinolones alone or multiply resistant were selected from the Enterobacteriaceae and Staphylococcus aureus by using sparfloxacin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1666499      PMCID: PMC245397          DOI: 10.1128/AAC.35.11.2423

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  In vitro activity of sparfloxacin.

Authors:  N X Chin; J W Gu; K W Yu; Y X Zhang; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  Mechanisms of quinolone resistance in a clinical isolate of Escherichia coli highly resistant to fluoroquinolones but susceptible to nalidixic acid.

Authors:  N Moniot-Ville; J Guibert; N Moreau; J F Acar; E Collatz; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

3.  The accumulation of five quinolone antibacterial agents by Escherichia coli.

Authors:  J M Diver; L J Piddock; R Wise
Journal:  J Antimicrob Chemother       Date:  1990-03       Impact factor: 5.790

4.  Genetic control of DNA initiation in Escherichia coli.

Authors:  W H Schubach; J D Whitmer; C I Davern
Journal:  J Mol Biol       Date:  1973-02-25       Impact factor: 5.469

5.  Uptake of sparfloxacin and norfloxacin by clinical isolates of Staphylococcus aureus.

Authors:  S Yoshida; T Kojima; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

6.  Correlation of quinolone MIC and inhibition of DNA, RNA, and protein synthesis and induction of the SOS response in Escherichia coli.

Authors:  L J Piddock; R N Walters; J M Diver
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

7.  Isolation and characterization of norfloxacin-resistant mutants of Escherichia coli K-12.

Authors:  K Hirai; H Aoyama; S Suzue; T Irikura; S Iyobe; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

8.  Inhibitory effects of quinolones on pro- and eucaryotic DNA topoisomerases I and II.

Authors:  N J Moreau; H Robaux; L Baron; X Tabary
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

9.  Broad-host-range gyrase A gene probe.

Authors:  N J Robillard
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

10.  Mechanisms of quinolone resistance in Escherichia coli: characterization of nfxB and cfxB, two mutant resistance loci decreasing norfloxacin accumulation.

Authors:  D C Hooper; J S Wolfson; K S Souza; E Y Ng; G L McHugh; M N Swartz
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

View more
  12 in total

1.  Novel ciprofloxacin-resistant, nalidixic acid-susceptible mutant of Staphylococcus aureus.

Authors:  Laura J V Piddock; Yu Fang Jin; Mark A Webber; Martin J Everett
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

2.  A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux.

Authors:  R Beyer; E Pestova; J J Millichap; V Stosor; G A Noskin; L R Peterson
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

Review 3.  New quinolones and gram-positive bacteria.

Authors:  L J Piddock
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

4.  Accumulation of 10 fluoroquinolones by wild-type or efflux mutant Streptococcus pneumoniae.

Authors:  Laura J V Piddock; M M Johnson
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

5.  Ciprofloxacin resistance in clinical isolates of Salmonella typhimurium obtained from two patients.

Authors:  L J Piddock; D J Griggs; M C Hall; Y F Jin
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

Review 6.  Mechanisms of resistance to quinolones.

Authors:  E Cambau; L Gutmann
Journal:  Drugs       Date:  1993       Impact factor: 9.546

7.  Activity of Bay y3118 against quinolone-susceptible and -resistant gram-negative and gram-positive bacteria.

Authors:  L J Piddock; A J Marshall; Y F Jin
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

8.  Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra.

Authors:  T Kocagöz; C J Hackbarth; I Unsal; E Y Rosenberg; H Nikaido; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

Review 9.  Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections.

Authors:  K L Goa; H M Bryson; A Markham
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

10.  Quinolone accumulation in Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus.

Authors:  C McCaffrey; A Bertasso; J Pace; N H Georgopapadakou
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.